Sean Pitroda to Neoplasms
This is a "connection" page, showing publications Sean Pitroda has written about Neoplasms.
Connection Strength
3.218
-
Nontumor Cells in Tumor Samples Bias Expression-Based Models-Reply. JAMA Oncol. 2024 Feb 01; 10(2):260-261.
Score: 0.315
-
Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization. Neoplasia. 2023 Feb; 36:100867.
Score: 0.292
-
Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2022 12; 54(12):1782-1785.
Score: 0.290
-
Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol. 2019 09; 16(9):581-588.
Score: 0.232
-
DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med. 2014 Mar 26; 6(229):229ra42.
Score: 0.159
-
Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104.
Score: 0.144
-
STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med. 2009 Nov 05; 7:68.
Score: 0.117
-
Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024 Aug; 25(8):e352-e362.
Score: 0.082
-
Radiotherapy and immunology. J Exp Med. 2024 Jul 01; 221(7).
Score: 0.080
-
Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest. 2023 12 15; 133(24).
Score: 0.078
-
RNA m6A methylation and MDSCs: Roles and therapeutic implications for radiotherapy. Med. 2023 Dec 08; 4(12):863-874.
Score: 0.078
-
Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition. Clin Cancer Res. 2023 08 01; 29(15):2761-2766.
Score: 0.076
-
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology. 2023; 12(1):2222560.
Score: 0.075
-
YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
Score: 0.075
-
The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
Score: 0.071
-
Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. Neoplasia. 2022 05; 27:100782.
Score: 0.069
-
Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022 01; 8(1):9-20.
Score: 0.067
-
Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res. 2021 10 01; 27(19):5188-5194.
Score: 0.067
-
Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. Int J Mol Sci. 2021 Sep 03; 22(17).
Score: 0.067
-
The Spectrum of Metastasis: An Opportunity for Cure? Semin Radiat Oncol. 2021 07; 31(3):174-179.
Score: 0.066
-
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
Score: 0.066
-
Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
Score: 0.064
-
(Oligo)metastasis as a Spectrum of Disease. Cancer Res. 2021 05 15; 81(10):2577-2583.
Score: 0.064
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
Score: 0.063
-
Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease. Cancer J. 2020 Mar/Apr; 26(2):96-99.
Score: 0.060
-
Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features. J Clin Oncol. 2019 05 20; 37(15):1270-1276.
Score: 0.056
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.052
-
DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells. Oncogene. 2016 12 15; 35(50):6439-6445.
Score: 0.046
-
Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
Score: 0.046
-
Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget. 2016 May 03; 7(18):26496-515.
Score: 0.046
-
14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015 Feb 28; 6(6):3540-52.
Score: 0.042
-
Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol. 2009 May; 85(5):421-31.
Score: 0.028
-
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
Score: 0.020
-
Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease. J Clin Oncol. 2024 Oct 10; 42(29):3387-3391.
Score: 0.020
-
Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
Score: 0.016
-
A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):189-195.
Score: 0.015
-
microRNAs and oligometastasis. Aging (Albany NY). 2015 Mar; 7(3):146-7.
Score: 0.011